RxDoctor Payments Data

Jon Grace, MD

Critical Care Medicine · Anchorage, AKNPI 1245573278

Payments from drug & device makers

What this record shows

The money is spread across several categories — education (50.0%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 86.7% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2023 at $6,285 and has fallen 93.4% since, to $414 in 2025.

$9,038in general payments, 2019–2025

Across 53 payments — averaging $170.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$8K
  • GSK$305
  • Sanofi$296
  • Baxter Healthcare$174
  • Blueprint Medicines Corporation$121
  • Takeda Pharmaceuticals U.S.A., Inc.$98
  • plus $205 from 7 others

What the payments were for

  • Travel & lodging$2,72730%
  • Food & beverage$1,79220%
  • Education$4,52050%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few critical care medicine providers in Alaskato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$266,325
Medicare patients
514
Services billed
2,455

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter176$150,924
Dupixent PenDupilumab20$88,479
Fasenra PenBenralizumab12$72,004
Breo ElliptaFluticasone/Vilanterol36$24,400
Spiriva RespimatTiotropium Bromide34$22,803
Stiolto RespimatTiotropium Br/Olodaterol Hcl40$20,021
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate11$2,612
Albuterol Sulfate HfaAlbuterol Sulfate34$1,804
Azithromycin41$1,376
Roflumilast13$1,320
Gabapentin15$763
Montelukast Sodium31$535
Prednisone84$512
Ipratropium Bromide11$283
MethotrexateMethotrexate Sodium15$250

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta$305$175,324212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few critical care medicine providers in Alaskaon file to place this against a meaningful peer group, so we don't.

Other critical care medicine in Anchorage

See the full list for Alaska

Where these figures come from

Is this you, or does something look wrong? →